Randomized, Double-Blind, Placebo-Controlled, Phase II Trial Of Short Course Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized (3.5 to 7cm) Hepatocellular Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 23 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 25 Mar 2016 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 14 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov record.